low but in the range of 1.0-2.0 ILmol/L, the higher samples may be prediluted before the assay is performed.
If the regular assay protocol is used (10-ILL sample, range of standards 100 to 2000 nmol/L), the low concentrations will not be measured accurately (<100 nmol/L). If the range of standards used is from 25-2000 nmol/L (with a 10-ILL sample size), the curve is very sensitive above 100 nmol/L but less so from 25 to 100 nmol/L. For example, the absorbance change with the full-range curve is 0.006 for concentrations from 25 to 50 nmol/L, whereas with the low-range curve the absorbance change is 0.026.
As many as 28 samples can be assayed in 3 mm. The alternative protocol allows the efficient and rapid measurement of samples obtained from patients receiving low-dose methotrexate therapy. The influence of metabolites on the assay remains undetermined. In particular, the metabolites 7-hydroxymethotrexate, 4-amino-4-deoxy-N'#{176}-methylpteroic acid, diglutamate, and triglutamate methotrexate should be examined for their effect on the assay, especially at very low concentrations of methotrexate.
Our experience has been largely the assay of samples from patients on usual or high-dose therapy, and we have found very low methotroxate concentrations in those patients after many days. This observation suggests that metabolites have no appreciable influence on the assay. However, patients receiving low-dose therapy with no concurrent citrovorum factor should be examined for metabolites to see if these influence the assay when the standard curve is deliberately set to detect very low concentrations. Demonstration of oligoclonal bands by electrophoresis of cerebrospinal fluid is an important aid in establishing the diagnosis of multiple sclerosis. Electrophoretic systems vary in their effectiveness in doing so. We compared two systems in this respect. For a thin-layer agarose system, sensitivity was less (47%) than for a high-resolution agarose system (87%). Each system had good specificity (92 and 85%, respectively).
Interpretation of electrophoretic patterns for cerebrospinal fluid should be available in clinical laboratories. Further, the best available system should be used for demonstration of oligoclonal bands.
AddItionalKeyphrase:multiple sclerosis
The role of the clinical laboratory in aiding in the diagnosis of multiple sclerosis has changed in recent years because of three procedures: demonstration of oligoclonal bands by agarose electrophoresis of cerebrospinal fluid (CSF) (1) (2, 4) , although oligoclonal bands in the CSF are not specific for demyelinating diseases (1, 5) . Methods used to demonstrate the oligoclonal bands may differ in sensitivity. Agarose is the electrophoretic support medium used most commonly, but the several commercially supplied variants of agarose electrophoretic techniques differ in many features. Previously, we assessed the performance characteristics of a commercial agarose electrophoretic system used to demonstrate oligoclonal bands (2) . Here, we compare the performance of that system with that of a high-resolution agarose electrophoretic system.
Cellulose acetate is known to be an inappropriate support medium for the demonstration of oligoclonal bands (6). Of these, the thin-layer system identified seven (sensitivity = 47%), the high-resolution system 13 (sensitivity = 87%). Clinically, multiple sclerosis was not considered to be the diagnosis in 89 patients. Of these, the thin-layer system demonstrated oligoclonal bands in seven (specificity = 92%), and the high-resolution system demonstrated oligoclonal bands in 13 (specificity = 85%).
Materials and Methods

Samples
Discussion
As interest grows in laboratory procedures for aiding diagnosis of multiple sclerosis, it is important to evaluate the performance of these procedures. We reported elsewhere these characteristics for one agarose-electrophoretic method for demonstrating the presence of oligoclonal bands (2) . Here, we demonstrate the high-resolution system to be more sensitive. The thin-layer system had a sensitivity of 77% in our previous study of 185 unselected patients (2) . We cannot explain the markedly diminished sensitivity of 47% in this study, but in any case sensitivity of the high-resolution system (87%) exceeds both of these figures. Specificities of 95% for the thinlayer system (99% in our previous study) and 85% for the high-resolution system are good, especially if one considers that the patients were not selected on the basis of suspected multiple sclerosis. Obviously, patients from whom CSF is submitted to the laboratory are to some extent selected, in that some process that may involve the central nervous system is suspected. Specificity would be expected to be higher for a properly selected population.
The apparent "false positives" should not be viewed as necessarily diminishing the value of the procedure.
Oligoclonal bands represent locally produced immunoglobulin of restricted heterogeneity (8) . Oligoclonal bands are known to occur in the electrophoretic pattern for CSF of patients with neurosyphilis, Guillain-Barr#{233}syndrome, bacterial and viral encephalitis, and axonal polyneuropathy;
in the proper clinical context their demonstration may be of value (2, 5, (9) (10) (11) . The patients in this present study in whom oligoclonal bands were present but in whom multiple sclerosis was not considered at all likely included one each with Guillain-Barr#{233} syndrome, herniated intervertebral disc, diabetic polyneuropathy, and meningoencephalitis.
The others had neurologic abnormalities that were not considered to be manifestations of multiple sclerosis.
This study and the others cited demonstrate the value of CSF electrophoresis.
It is important to recognize the marked difference in the ability of different systems to identify the presence of oligoclonal bands. Interpretation of CSF electrophoretic patterns should be routinely available in clinical laboratories that already are offering protein electrophoresis. The performance characteristics of a system must be considered when choosing a method to demonstrate oligoclonal bands, as their presence or absence is becoming more important in the classification and management of patients. We urge providers of laboratory services to use systems that have well-defined and acceptable performance characteristics. 
Materials and Methods
Phenothiazines.
Prepare anion-exchange columns as follows. Weight lOg of AG 1-X4 anion-exchange resin, chloride form, 200-400 mesh (Bio-Rad Laboratories, Richmond, CA 94804) into a 125-mL Erlenmeyer flask. Add 35 mL of deionized water and stir. Add 0.5 mL of the anion exchange slurry into a Pasteur pipette containing a small cotton plug. This will produce an ion-exchange column that is about 1 cm X 4mm i.d. Add 1.0 mL of the urine to be tested for phenothiazines to this ion-exchange column. Discard the eluate; it will contain no detectable phenothiazine but may contain small amounts of ascorbic acid, depending on the original ascorbic acid concentration in the urine. Add 1.0 mL of deionized water to the column and collect the eluate. This eluate will contain phenothiazine if present in the original urine sample. Add 1.0 mL of Forrest's FPN reagent (1) to the collected eluate. A phenothiazine will be indicated by a pink or purple color. 
